Nanjing Iaso Biotechnology Co., Ltd.

This early-stage study is testing a new treatment called UB-VV410 in adults whose lupus or lupus-related kidney disease is still active despite standard treatments. The main goals are to find the safest and most effective dose and to check for any side effects. Researchers will a…

This early-stage study is testing the safety and initial effectiveness of a new drug called UB-VV400, both alone and combined with an existing drug called rapamycin. It is for adults with aggressive B-cell lymphoma that has come back or stopped responding to other treatments, inc…